88 related articles for article (PubMed ID: 1457190)
41. Control of IgE responses. 4. Isotype-specific suppression of peak BPO-specific IgE antibody-forming cell responses and of BPO-specific IgE in serum by muramyldipeptide or murabutide after administration to mice by gavage.
Auci DL; Carucci JA; Chice SM; Smith MC; Dukor P; Durkin HG
Int Arch Allergy Immunol; 1993; 101(2):167-76. PubMed ID: 8508053
[TBL] [Abstract][Full Text] [Related]
42. Enhanced antibody response to liposome-associated protein antigens: preferential stimulation of IgG2a/b production.
Phillips NC; Emili A
Vaccine; 1992; 10(3):151-8. PubMed ID: 1557930
[TBL] [Abstract][Full Text] [Related]
43. Als3-Th-cell-epitopes plus the novel combined adjuvants of CpG, MDP, and FIA synergistically enhanced the immune response of recombinant TRAP derived from Staphylococcus aureus in mice.
Ma J; Liu W; Wang B; Yu S; Yu L; Song B; Yu Y; Zhu Z; Cui Y
Immun Inflamm Dis; 2021 Sep; 9(3):971-983. PubMed ID: 34010502
[TBL] [Abstract][Full Text] [Related]
44. Molecular adjuvants based on nonpyrogenic lipophilic derivatives of norAbuMDP/GMDP formulated in nanoliposomes: stimulation of innate and adaptive immunity.
Knotigová PT; Zyka D; Mašek J; Kovalová A; Křupka M; Bartheldyová E; Kulich P; Koudelka Š; Lukáč R; Kauerová Z; Vacek A; Horynová MS; Kozubík A; Miller AD; Fekete L; Kratochvílová I; Ježek J; Ledvina M; Raška M; Turánek J
Pharm Res; 2015 Apr; 32(4):1186-99. PubMed ID: 25630814
[TBL] [Abstract][Full Text] [Related]
45. Formulation of a potential antipregnancy vaccine based on the beta-subunit of human chorionic gonadotropin (beta-hCG). II. Use of compounds of the muramyl dipeptide (MDP) family as adjuvants.
Nash HA; Chang CC; Tsong YY
J Reprod Immunol; 1985 Feb; 7(2):151-62. PubMed ID: 3981488
[TBL] [Abstract][Full Text] [Related]
46. Cytokine-containing liposomes as adjuvants for HIV subunit vaccines.
Lachman LB; Shih LC; Rao XM; Hu X; Bucana CD; Ullrich SE; Cleland JL
AIDS Res Hum Retroviruses; 1995 Aug; 11(8):921-32. PubMed ID: 7492439
[TBL] [Abstract][Full Text] [Related]
47. Involvement of gamma interferon in antibody enhancement by adjuvants.
Odean MJ; Frane CM; Van derVieren M; Tomai MA; Johnson AG
Infect Immun; 1990 Feb; 58(2):427-32. PubMed ID: 2105274
[TBL] [Abstract][Full Text] [Related]
48. Adamantylamide dipeptide as effective immunoadjuvant in rabbits and mice.
Becker PD; Corral RS; Guzmán CA; Grinstein S
Vaccine; 2001 Sep; 19(32):4603-9. PubMed ID: 11535307
[TBL] [Abstract][Full Text] [Related]
49. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity.
Allison AC; Byars NE
J Immunol Methods; 1986 Dec; 95(2):157-68. PubMed ID: 3540125
[TBL] [Abstract][Full Text] [Related]
50. Glucosaminylmuramyl dipeptide-induced changes in murine macrophage metabolism.
Balitsky KP; Umansky VY; Tarakhovsky AM; Andronova TM; Ivanov VT
Int J Immunopharmacol; 1989; 11(5):429-34. PubMed ID: 2553620
[TBL] [Abstract][Full Text] [Related]
51. Adjuvant activity of non-ionic block copolymers. IV. Effect of molecular weight and formulation on titre and isotype of antibody.
Hunter R; Olsen M; Buynitzky S
Vaccine; 1991 Apr; 9(4):250-6. PubMed ID: 2058267
[TBL] [Abstract][Full Text] [Related]
52. Immunological adjuvants: desirable properties and side-effects.
Allison AC; Byars NE
Mol Immunol; 1991 Mar; 28(3):279-84. PubMed ID: 1850114
[TBL] [Abstract][Full Text] [Related]
53. Adjuvant activity of non-ionic block copolymers. V. Modulation of antibody isotype by lipopolysaccharides, lipid A and precursors.
Takayama K; Olsen M; Datta P; Hunter RL
Vaccine; 1991 Apr; 9(4):257-65. PubMed ID: 2058268
[TBL] [Abstract][Full Text] [Related]
54. Generation of antibodies against recombinant HIV-gp120 antigen through a novel immunization procedure.
Matour DL; Clark RK; Jonak ZL
J Immunol Methods; 1991 Jun; 140(1):135-8. PubMed ID: 2061610
[No Abstract] [Full Text] [Related]
55. The effect of glucosaminylmuramyl dipeptide injection to mice on the course of tuberculous infection and in vitro superoxide anion production.
Venkataprasad N; Ledger P; Ivanyi J
Int Arch Allergy Immunol; 1997 Sep; 114(1):23-9. PubMed ID: 9303327
[TBL] [Abstract][Full Text] [Related]
56. Interferon-gamma as an adjuvant in immunocompromised mice.
Heath AW; Devey ME; Brown IN; Richards CE; Playfair JH
Immunology; 1989 Aug; 67(4):520-4. PubMed ID: 2504662
[TBL] [Abstract][Full Text] [Related]
57. [Experimental multifactorial study of the effect of doxycycline and glucosaminylmuramyl dipeptide on the primary immunologic response to antigens of a tularemia vaccine strain].
Nikitin AV; Andronova TM; Kovalenko LP; Fishman VM; Sheptovitskaia MG
Antibiot Med Biotekhnol; 1985 May; 30(5):360-4. PubMed ID: 4026257
[TBL] [Abstract][Full Text] [Related]
58. A purified saponin acts as an adjuvant for a T-independent antigen.
White AC; Cloutier P; Coughlin RT
Adv Exp Med Biol; 1991; 303():207-10. PubMed ID: 1805566
[TBL] [Abstract][Full Text] [Related]
59. Polyprenyl Phosphates Induce a High Humoral and Cellular Response to Immunization with Recombinant Proteins of the Replicative Complex of the Hepatitis C Virus.
Masalova OV; Lesnova EI; Onishchuk AA; Ivanova AM; Gerasimova EV; Ivanov AV; Narovlyansky AN; Sanin AV; Pronin AV; Kushch AA
Dokl Biochem Biophys; 2018 Sep; 482(1):261-263. PubMed ID: 30397888
[TBL] [Abstract][Full Text] [Related]
60. Formulation of vaccine adjuvant muramyldipeptides. 3. Processing optimization, characterization, and bioactivity of an emulsion vehicle.
Lidgate DM; Fu RC; Byars NE; Foster LC; Fleitman JS
Pharm Res; 1989 Sep; 6(9):748-52. PubMed ID: 2813271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
